고시 수재 의약품의 용출규격 설정 - 구연산니카메테이트 정, 노르플록사신 캡슐 = Establishment of Dissolution Specifications for Generic Drugs in Korea Pharmaceutical Codex Monograph - Nicametate Citrate Tablet, Norfloxacin Capsule

다국어 초록 (Multilingual Abstract)

Despite the fact that the dissolution test can serve as an effective tool for drug quality control and prediction of in vivo drug performance, there are a number of drugs with no established dissolution specifications because they were developed quite a long time ago. Under this circumstances, KFDA started the new project that establishes dissolution method and specifications for drugs with no dissolution specifications listed in the Korea Pharmaceutical Codex (KPC). This project aims for promoting the appropriate management of oral solid dosage forms. Seoul regional KFDA selected 2 items, Nicametate citrate tablet and Norfloxacin capsule, for establishing dissolution specifications. We went through the following procedures to develop the dissolution method and specifications: (1) Validation of dissolution test equipment, (2) Purchase of test drugs, (3) Preliminary test with one of the test products (1 lot), (4) Validation of analysis methods (3 lots), (5) Final tests and cross tests among other laboratory to establish dissolution specifications, (6) Additional test with the other test drugs. The outcome of this study will be reflected in revision of the KPC. It is believed that the quality control and evaluation of oral solid dosage forms listed in KPC will be advanced with the revision which adds additional dissolution test and specifications for the drugs with no established dissolution specifications.

참고문헌 (Reference)

1 식품의약품안전청, "의약품등의 품목허가·신고·심사 규정"

2 식품의약품안전청, "의약품동등성시험관리규정"

3 식품의약품안전청, "의약품 등 시험방법 밸리데이션에 대한 가이드라인 적용을 위한 해설서"

4 식품의약품안전청, "대한약전외의약품등기준 제3개정"

5 식품의약품안전청, "대한약전 제9개정"

6 이종기, "노르플록사신의 체내동태에 대한 신장해의 영향" 25 (25): 265-, 1995

7 식품의약품안전청, "경구용의약품의 용출규격 설정 가이드라인"

8 The United States Pharmacopoeia 32, "United States Pharmacopoeial Convention"

9 "The Japanese Pharmacopoeia 15th"

10 EMEA, "Summary of Requirements for Active Substance in Quality Part of the Dossier"

11 EMEA, "Specifications and Control Tests on the Finished Product"

12 EMEA, "Investigation of Chiral Active Substance"

13 ICH, "ICHQ6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products:Chemical Substances"

14 ICH, "ICH Q8 Pharmaceutical development"

15 FDA, "Guidance for Industry Drug Substance Chemistry,Manufacturing, and Controls Information"

16 "European Pharmacopoeia 6"

17 EMEA, "Chemistry of New Active Substance"

18 "British Pharmacopoeia 2008"

19 EMEA, "Active Substance Master File Procedure"